Copyright
©The Author(s) 2016.
World J Gastroenterol. Jun 21, 2016; 22(23): 5400-5405
Published online Jun 21, 2016. doi: 10.3748/wjg.v22.i23.5400
Published online Jun 21, 2016. doi: 10.3748/wjg.v22.i23.5400
Table 4 Adverse events (CTC AE3.0)
| Patient | I°-II° | III°-IV° | Total |
| Fatigue | 70% (7/10) | 30% (3/10) | 100% |
| Nausea | 20% (2/10) | 0% (0/10) | 20% |
| Emesis | 20% (2/10) | 10% (1/10) | 30% |
| Diarrhea | 40% (4/10) | 0% (0/10) | 40% |
| Mukositis | 30% (3/10) | 10% (1/10) | 40% |
| Rash | 20% (2/10) | 0% (0/10) | 20% |
| HFS | 30% (3/10) | 0% (0/10) | 30% |
| PNP | 20% (2/10) | 0% (0/10) | 20% |
| Pain | 20% (2/10) | 10% (1/10) | 30% |
| Weight loss | 10% (1/10) | 0% (0/10) | 10% |
| Infection | 20% (2/10) | 0% (0/10) | 20% |
| Anemia | 40% (4/10) | 20% (2/10) | 60% |
| Thrombopenia | 30% (3/10) | 10% (1/10) | 40% |
| Leucopenia | 20% (2/10) | 10% (1/10) | 30% |
- Citation: Martchenko K, Schmidtmann I, Thomaidis T, Thole V, Galle PR, Becker M, Möhler M, Wehler TC, Schimanski CC. Last line therapy with sorafenib in colorectal cancer: A retrospective analysis. World J Gastroenterol 2016; 22(23): 5400-5405
- URL: https://www.wjgnet.com/1007-9327/full/v22/i23/5400.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i23.5400